Dosist debuts topical line

The line of dosist health CBD+ products includes a lotion, a roll-on and a spray. 
David Salazar
Managing Editor
David Salazar profile picture

CBD and wellness brand dosist is launching its dosist health brand with a lineup of topical products with CBD in three formats. The line of dosist health CBD+ products includes a lotion, a roll-on and a spray. 

"We spent the last 3 years developing topical analgesics formulated with precise measurements of cannabinoids and natural botanical ingredients in addition to sophisticated absorption technology to help mitigate pain and inflammation," said Jason DeLand, executive chairman and co-founder of dosist. "We believe that happiness is the highest form of health, and each product within our dosist health CBD+ category is thoughtfully and scientifically engineered to help people improve their quality of life."

The dosist Topical Performance Spray includes a proprietary nanoblend technology — which combines CBD and cannabigerol, or CBG, as well as cannabichromene, or CBC —meant to allow for rapid absorption. The product is designed with athletes in mind and contains capsicum, menthol and arnica alongside the cannabinoids. It contains 750 mg of cannabinoids per bottle and has a suggested retail price of $49.

The line’s Topical CBD Lotion and Topical CBD Roll-On each combine rations of CBD and CBG with active plant ingredients to offer a formula that can help relieve pain and inflammation. The Topical CBD Lotion — which contains 825 mg of cannabinoids per bottle, has a suggested retail price of $44.  The Topical CBD Roll-On has a suggested price of $38, with each roll-on 

"Cannabinoids, terpenes and natural phytochemicals are incredible natural conduits in helping many quality-of-life needs that modern consumers face," DeLand said.  "It is our mission to optimize these elements to unlock these needs through our scientific formulas, precision dosage and increased bioavailability, and we are thrilled to bring this platform to the topical pain relief category across the US today."